Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 
The good —  AstraZeneca’s Tagrisso delivers 84% progression-free survival in trial 
The bad — BMS to let go of 863 employees at NJ site  
The ugly — FDA inspection uncovers multiple violations at Jiangsu Hengrui Pharmaceuticals site

FDA backs Lilly Alzheimer’s drug; Pfizer Duchenne gene therapy fails; Talc plaintiffs seek J&J bankruptcy restraining order  [The good, the bad, the ugly]

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more